NetraMark Holdings Inc. recently completed a Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA) regarding its explainable AI/ML platform, NetraAI. The CPIM served as a non-regulatory, non-binding scientific exchange in which the FDA provided feedback on NetraAI's use as an enrichment methodology in clinical trial design. The FDA discussed NetraAI’s approach to predictive enrichment and considerations for identifying responder-enriched subgroups, but the meeting did not constitute regulatory approval or endorsement. The FDA also suggested that NetraMark consider engaging in the Model-Informed Drug Development (MIDD) Paired Meeting Program for further scientific dialogue. No grant or funding was mentioned in connection with the regulatory review.